Optimisation of Healthcare Contracts: Tensions Between Standardisation and Innovation; Comment on “Competition in Healthcare: Good, Bad or Ugly?”

نویسندگان

  • Misja Mikkers NZa, Dutch Healthcare Authority, Utrecht, The Netherlands | Free University of Amsterdam, Amsterdam, The Netherlands | TILEC, Tilburg University, Tilburg, The Netherlands
  • Padhraig Ryan Centre for Health Policy and Management, Trinity College Dublin, Dublin 2, Ireland
چکیده مقاله:

An important determinant of health system performance is contracting. Providers often respond to financial incentives, despite the ethical underpinnings of medicine, and payers can craft contracts to influence performance. Yet contracting is highly imperfect in both single-payer and multi-payer health systems. Arguably, in a competitive, multi-payer environment, contractual innovation may occur more rapidly than in a single-payer system. This innovation in contract design could enhance performance. However, contractual innovation often fails to improve performance as payer incentives are misaligned with public policy objectives. Numerous countries seek to improve healthcare contracts, but thus far no health system has demonstrably crafted the necessary blend of incentives to stimulate optimal contracting.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

optimisation of healthcare contracts: tensions between standardisation and innovation; comment on “competition in healthcare: good, bad or ugly?”

an important determinant of health system performance is contracting. providers often respond to financial incentives, despite the ethical underpinnings of medicine, and payers can craft contracts to influence performance. yet contracting is highly imperfect in both single-payer and multi-payer health systems. arguably, in a competitive, multi-payer environment, contractual innovation may occur...

متن کامل

Optimisation of Healthcare Contracts: Tensions Between Standardisation and Innovation: Comment on "Competition in Healthcare: Good, Bad or Ugly?".

An important determinant of health system performance is contracting. Providers often respond to financial incentives, despite the ethical underpinnings of medicine, and payers can craft contracts to influence performance. Yet contracting is highly imperfect in both single-payer and multi-payer health systems. Arguably, in a competitive, multi-payer environment, contractual innovation may occur...

متن کامل

Competition in Healthcare: Good, Bad or Ugly?

The role of competition in healthcare is much debated. Despite a wealth of international experience in relation to competition, evidence is mixed and contested and the debate about the potential role for competition is often polarised. This paper considers briefly some of the reasons for this, focusing on what is meant by “competition in healthcare” and why it is more valuable to think about th...

متن کامل

competition in healthcare: good, bad or ugly?

the role of competition in healthcare is much debated. despite a wealth of international experience in relation to competition, evidence is mixed and contested and the debate about the potential role for competition is often polarised. this paper considers briefly some of the reasons for this, focusing on what is meant by “competition in healthcare” and why it is more valuable to think about th...

متن کامل

Competition in Healthcare: Good, Bad or Ugly?

The role of competition in healthcare is much debated. Despite a wealth of international experience in relation to competition, evidence is mixed and contested and the debate about the potential role for competition is often polarised. This paper considers briefly some of the reasons for this, focusing on what is meant by "competition in healthcare" and why it is more valuable to think about th...

متن کامل

Investment Policy Medical Megamorphosis Healthcare reform : The Good , The Bad or The Ugly ?

Highlights Q The Good: Sweeping reform plan does not pass because it is too costly to be financed without huge taxes. But, healthcare disinflation continues; drug companies keep their pricing increases to CPI or CPI + 1%. Health supply/device stocks unit growth flattens, but best companies still achieve 12-15% growth. Firms withdraw from marginal businesses, trim sales forces/product lines and ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


عنوان ژورنال

دوره 5  شماره 2

صفحات  121- 123

تاریخ انتشار 2016-02-01

با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023